Search company, investor...

OncoMed Pharmaceuticals

Founded Year



Acq - P2P | Acquired

Total Raised




About OncoMed Pharmaceuticals

OncoMed Pharmaceuticals is a clinical-stage company focused on discovering and developing therapeutics targeting cancer stem cells, or CSCs, which are the subpopulation of cells in a tumor responsible for driving growth and metastasis of the tumor.

Headquarters Location

800 Chesapeake Drive

Redwood City, California, 94063,

United States


Missing: OncoMed Pharmaceuticals's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: OncoMed Pharmaceuticals's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing OncoMed Pharmaceuticals

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

OncoMed Pharmaceuticals is included in 3 Expert Collections, including Cancer.



1,179 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.


Regenerative Medicine

1,818 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).


Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

OncoMed Pharmaceuticals Patents

OncoMed Pharmaceuticals has filed 148 patents.

The 3 most popular patent topics include:

  • Monoclonal antibodies
  • Immunology
  • Clusters of differentiation
patents chart

Application Date

Grant Date


Related Topics




Monoclonal antibodies, Immunology, Experimental cancer drugs, Clusters of differentiation, Immune system


Application Date


Grant Date



Related Topics

Monoclonal antibodies, Immunology, Experimental cancer drugs, Clusters of differentiation, Immune system



Latest OncoMed Pharmaceuticals News

Immune-Onc Therapeutics Appoints Two New Members to its Board of Directors

Nov 8, 2022

Austin L. Gurney, Ph.D. and Barbara J. Klencke, M.D. bring deep expertise in oncology drug discovery and development November 08, 2022 09:30 AM Eastern Standard Time PALO ALTO, Calif.--( BUSINESS WIRE )--Immune-Onc Therapeutics, Inc. (“Immune-Onc”), a private, clinical-stage cancer immunotherapy company developing novel biotherapeutics targeting myeloid checkpoints, today announced the appointments of Austin L. Gurney, Ph.D. and Barbara J. Klencke, M.D. to the company’s board of directors. "We are excited and honored to welcome two well-known and respected biopharmaceutical leaders to our Board of Directors, joining us in our mission to develop novel myeloid checkpoint inhibitors for cancer patients,” said Charlene Liao, Ph.D., founder, chief executive officer and chair of Immune-Onc. "Austin and Barbara have a deep understanding of the discovery and development process for breakthrough cancer therapies, experience that both complements and expands the expertise of our Board. Our company and patients will benefit from their R&D leadership and perspectives." “Immune-Onc’s pioneering role in developing myeloid checkpoint inhibitors as next generation immunotherapies has impressed me,” said Dr. Gurney. “I am excited to work with the team to advance its growing portfolio of first-in-class and potentially best-in-class molecules through research and development, and ultimately to patients.” “Immune-Onc’s pipeline of novel myeloid checkpoint inhibitors represents a new and promising therapeutic approach for the treatment of solid tumors and hematologic malignancies,” said Dr. Klencke. “It is a privilege to join the Board and I look forward to working with the leadership team to help progress the clinical development of this exciting new class of immunotherapy.” Austin Gurney, Ph.D. is a biotech industry veteran with over two decades of experience in the discovery and development of novel therapeutics. He was chief scientific officer, senior vice president of research at OncoMed Pharmaceuticals where he held various management roles of increasing responsibility between 2004 and 2017. During this time, he and his teams discovered and developed five first-in-class therapeutic agents. Prior to OncoMed, Austin worked at Genentech where his research led to the discovery of several growth factors and cytokines. He has authored or co-authored more than 60 published scientific papers and is listed as an inventor on over 600 patents related to therapeutic applications in immunology and cancer. Austin received his Ph.D. in biology from Case Western Reserve University. Barbara J. Klencke, M.D. is a world-class drug developer and research & development expert, having made significant contributions to the oncology community with the development and approval of several first-in-class therapies. Since 2015, she has served as the chief medical officer of Sierra Oncology Inc., a publicly traded clinical-stage biopharmaceutical company recently acquired by GSK in 2022. From 2011 to 2015, Barbara served as senior vice president of global development at Onyx Pharmaceuticals, acquired by Amgen Inc. in 2013. She also led a variety of both early- and late-stage oncology programs while at Genentech, Inc. from 2003 to 2011. Barbara received her M.D. from the University of California, Davis (UC Davis) and completed her internal medicine residency and hematology/oncology fellowship at the University of California, San Francisco (UCSF) and remained at UCSF as an assistant professor of medicine in oncology focusing on clinical research from 1995 – 2002. ABOUT IMMUNE-ONC THERAPEUTICS, INC. Immune-Onc Therapeutics Inc. (“Immune-Onc”) is a private, clinical-stage cancer immunotherapy company dedicated to the discovery and development of novel myeloid checkpoint inhibitors for cancer patients. The company aims to translate unique scientific insights in myeloid cell biology and immune inhibitory receptors to discover and develop first-in-class biotherapeutics that inhibit immune suppression in the tumor microenvironment. Immune-Onc has a differentiated pipeline with a current focus on targeting the Leukocyte Immunoglobulin-Like Receptor subfamily B (LILRB) of myeloid checkpoints. Immune-Onc’s focused platform approach has led to the development of several promising therapeutics across various stages of development. Those include IO-108, an antagonist antibody targeting LILRB2 (also known as ILT4), in Phase 1 clinical development for solid tumors and IO-202, a first-in-class antagonist antibody targeting LILRB4 (also known as ILT3), in Phase 1 clinical development for the treatment of acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML), and solid tumors. Additional assets in Immune-Onc’s pipeline include IO-106 (first-in-class antagonist antibody targeting LAIR1), IO-312 (bi-specific antibody targeting LILRB4), and multiple undisclosed programs for solid tumors and hematologic malignancies. Immune-Onc has established agreements with leading biopharmaceutical companies, including BeiGene and Regeneron , to support its global product development plans for IO-108 and IO-202. It has received research grants from the National Cancer Institute (NCI) of the National Institutes of Health (NIH) and the California Institute for Regenerative Medicine (CIRM) and investment from The Leukemia & Lymphoma Society Therapy Acceleration Program® (LLS TAP®). Headquartered in Palo Alto, California, Immune-Onc has assembled a diverse team with deep expertise in drug development and proven track records of success at leading biopharmaceutical companies. For more information, please visit and follow us on Twitter and LinkedIn . Contacts

OncoMed Pharmaceuticals Frequently Asked Questions (FAQ)

  • When was OncoMed Pharmaceuticals founded?

    OncoMed Pharmaceuticals was founded in 2004.

  • Where is OncoMed Pharmaceuticals's headquarters?

    OncoMed Pharmaceuticals's headquarters is located at 800 Chesapeake Drive, Redwood City.

  • What is OncoMed Pharmaceuticals's latest funding round?

    OncoMed Pharmaceuticals's latest funding round is Acq - P2P.

  • How much did OncoMed Pharmaceuticals raise?

    OncoMed Pharmaceuticals raised a total of $294.6M.

  • Who are the investors of OncoMed Pharmaceuticals?

    Investors of OncoMed Pharmaceuticals include Mereo BioPharma, Morgenthaler Ventures, The Vertical Group, U.S. Venture Partners, Nomura Holdings and 10 more.

  • Who are OncoMed Pharmaceuticals's competitors?

    Competitors of OncoMed Pharmaceuticals include Stemina Biomarker Discovery, Esperance Pharmaceuticals, Endocare, PNP Therapeutics, GANYMED Pharmaceuticals, Reata Pharmaceuticals, Stemcentrx, Syndax Pharmaceuticals, Affimed Therapeutics, GlobeImmune and 24 more.

Compare OncoMed Pharmaceuticals to Competitors

Esperance Pharmaceuticals

Esperance Pharmaceuticals develops targeted anticancer drugs that selectively kill cancer cells without harming normal cells.

Marillion Pharmaceuticals

Marillion Pharmaceuticals, Inc. - Marillion is developing clinical-stage drugs in oncology and oncology supportive care. 177Lu-AMBA is a targeted radiotherapeutic, with the low level radiation of lutetium that aims to utilize an receptor-based technology, and can serve as both a diagnostic and therapeutic agent. The targeting capability means that 177Lu-AMBA homes in on tumor cells and spares normal tissues. 177Lu-AMBA is being pursued initially to treat hormone-resistant prostate cancer, has been studied in a phase I trial in Europe. Marillion also is developing PilobucTM , buccal formulation of pilocarpine ,for the treatment of dry mouth, shown in clinical trials to effectively and conveniently deliver the drug with reduced side effects compared to other routes of administration.PilobucTM buccal formulation of pilocarpine has the potential to be a product in the xerostomia market. Marillion is preparing for phase II trials of the product candidate..


Onyvax is developing new cancer therapies that harness the selective power of the immune system to seek out and destroy tumor cells. Onyvax's products specifically target cancer cells, increasing the likelihood that they will be effective while minimising side effects associated with many conventional treatments. These therapies can broadly be classed as therapeutic cancer vaccines. Onyvax's lead product is in clinical trials for the treatment of prostate cancer and is poised to enter the final stages of development. Onyvax is committed to the commercialisation of therapies that enhance survival while maintaining a high quality of life for patients. The Company is based in London and has collaborations with leading hospitals and other institutions throughout Europe and the US.


NovoCell, Inc./BresaGen is a stem cell engineering company dedicated to creating, delivering, and commercializing cell and drug therapies to treat diabetes and other chronic diseases. Novocell uses its cell encapsulation technology and expertise in cell implantation to develop a renewable source of specialized cells for the treatment of cellular diseases. Bresagen represents a division of Novocell's research operation.

The DNA Repair Company

The DNA Repair Company was founded to bring recent scientific discoveries from the Dana Farber Cancer Institute and the Massachusetts Institute of Technology to the clinic to benefit cancer patients. Breakthroughs in understanding DNA repair mechanisms have led to new personalized approaches to cancer treatment, beginning with diagnostic tools that improve the efficacy of currently available cancer therapies, as well as drugs under development. DNAR exists to make these tools available to physicians with the goal of improving clinical outcomes.

Activate Immunotherapy

Activate Immunotherapy (formerly NovaRx) is a clinical-stage immuno-oncology company based in San Diego, California. Activate utilizes a novel approach for activating the body's immune system to recognize and destroy cancer cells. The company's most advanced immunotherapy, Lucanix, has been tested in late stage clinical trials as a treatment for non-small cell lung cancer (NSCLC), the largest cancer indication in the world. Lucanix has promising Phase 2 and Phase 3 data. In Lucanix's Phase 2 trial, the company demonstrated a significant improvement in survival for NSCLC patients. NovaRx completed a 532 patient Phase 3 study in early 2013. While the Phase 3 study missed the statistical endpoint for approval, survival benefits were shown if non United States clinical sites were excluded, particularly with patients who started Lucanix treatment within 12 weeks of chemotherapy and/or patients with prior chemotherapy and radiation therapy. Activate's proprietary platform technology is applicable to other solid tumors.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.